PD-L1 Inhibition as ChecKpoint Immunotherapy for NeuroEndocrine Phenotype Prostate Cancer

NCT03179410 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
15
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Andrew J. Armstrong, MD